Description du projet
Adieu les forceps, bonjour l’aspiration sous‑vide douce pour les procédures gynécologiques courantes
Les dispositifs intra‑utérins (DIU) sont la forme de contraception la plus efficace, excepté la stérilisation et l’abstinence. En dépit de cela, un grand pourcentage de femmes les évitent du fait des complications liées à leur implantation: douleurs, saignements et contamination croisée. Le projet Aspivix, financé par l’UE, apporte sur le marché un instrument chirurgical révolutionnaire qui remplacera les forceps, les traditionnelles pinces cervicales. Aspivix est un dispositif à usage unique reposant sur une ventouse d’aspiration sous‑vide douce pour stabiliser le col de l’utérus au cours de procédures gynécologiques, dont l’implantation d’un DIU. Non seulement ce dispositif permettra de réduire l’inconfort et les risques pour les patientes, mais il simplifiera et accélèrera également la procédure d’implantation, apportant ainsi des avantages financiers supplémentaires.
Objectif
For years, gynecologist practices related to Intra-Uterine Contraceptive Device (IUD) insertions, curettage and several other common indications, have featured poor care and low attention to female patients.
The use of the Tenaculum, grasping and pulling on the cervix, inside the vaginal cavity, proved to be painful and traumatic for 84% of the women, and eventually to trigger lesions and bleeding in 29% of the patients, as well as cross-contamination in 5-10% of the women. These disadvantages refrain the use of IUD contraceptive which exacerbates the unintended pregnancies, sized yearly in 85 mills and representing billions of euros in social costs worldwide.
In response, we have developed Aspivix, a new disruptive gynecological device that reduces the pain and eradicates the bleeding during the exploration procedure. Our patented device will replace the Tenaculum forceps, unchanged for over 100 years, to provide gynecologists an easy-to-use device where gentle and firm cervix uterus grasping and traction is needed. Thus, our device will facilitate the adoption of IUD, which could avoid up to 8% of unintended pregnancies and reduce derived social costs. Besides, Aspivix is intended for a single use which prevents the risk of contamination and cross-infection. Overall, Aspivix has the potential to shorten the intervention procedure (2 steps instead 7), which will represent for the physician a 28% economic benefit. As result, Aspivix will fulfill the needs of more than 64 M of women worldwide/year, a market that is projected to grow at a CAGR2016-2021 of ~6.5% due to the high demand of IUD insertions and is valued in more than €385M.
Champ scientifique
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
1020 RENENS
Suisse
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.